Use of phenol derivative in treatment of fibrosis
By developing phenol derivative compounds to block EMT and FMT processes and inhibit excessive ECM deposition, the problems of tissue remodeling and organ dysfunction caused by fibrosis have been solved, achieving effective prevention and treatment of various fibrotic diseases.
Patent Information
- Application Number
- PCT/CN2025/093955
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-09
- Publication Date
- 2026-11-12
AI Technical Summary
Existing technologies are insufficient to effectively control the fibrosis process, leading to tissue remodeling and organ dysfunction, which seriously threatens human health and life.
We developed phenol derivative compounds that significantly inhibited excessive extracellular matrix (ECM) deposition by blocking epithelial-mesenchymal transition (EMT) and fibroblast-myofibroblast transition (FMT), thereby achieving precise regulation of fibrosis.
Compounds P1 and P2 significantly inhibited EMT and FMT processes and reduced ECM deposition in in vitro models, demonstrating significant anti-fibrotic activity and potential for the prevention and treatment of various fibrotic diseases.
Smart Images

Figure CN2025093955_12112026_PF_FP_ABST
Abstract
Description
Application of phenol derivatives in the treatment of fibrosis Technical Field
[0001] This invention belongs to the field of medicine, specifically relating to the application of a phenol derivative in the treatment of fibrosis. Background Technology
[0002] Fibrosis is a chronic pathological process triggered by various pathological injuries (such as inflammation, ischemia, and metabolic abnormalities). It is characterized by damage to organ parenchymal cells, an imbalance between the synthesis and degradation of extracellular matrix (ECM), and abnormal accumulation of ECM components (such as collagen and fibronectin). This process can lead to tissue remodeling and organ dysfunction, ranging in severity from mild fibrosis to irreversible organ sclerosis. Fibrosis can affect multiple organs, including the lungs, liver, kidneys, and heart. The main pathological changes include proliferation of fibrous connective tissue, reduction of parenchymal cells, and excessive ECM deposition. If not effectively controlled, fibrosis can progress to organ structural destruction and functional decline, ultimately leading to organ failure, seriously threatening human health and life.
[0003] Developing new anti-fibrotic drugs, especially those that can precisely regulate key pathological processes in fibrosis, is an urgent need for the prevention and treatment of fibrosis. Summary of the Invention
[0004] This invention provides the use of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an antifibrotic drug;
[0005] Where A is selected from
[0006] R1 and R2 may be the same or different, and are independently selected from halogens and C. 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 alkyl;
[0007] R3 is selected from hydrogen, halogen, CN, OH, -OR a -NR c R d -C(=O)R a -C(=O)OR b -C(=O)NR c R dC 1-6 Alkyl, Halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 Alkyl; each R a R b R c R d Whether the two are the same or different, they are selected independently from H and C. 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 alkyl;
[0008] R4 is selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 alkyl;
[0009] L is selected from unsubstituted or optionally by one, two or more R. L Replaced sub-C 1-6 Alkyl; each R L They may be the same or different, and are independently selected from halogens, CN, OH, and C. 1-6 Alkyl, C 6-14 Aryl, 5-14 heteroaryl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 Alkyl; or two R L Composed of spirocyclic, aromatic, heterocyclic, or carbocyclic rings;
[0010] X is selected from N or CR x ;
[0011] Y is selected from N or CR y ;
[0012] Z is selected from N or CR. z And at most two of X, Y, and Z are N;
[0013] R x R y R z They are the same or different, and are independently selected from halogens and C. 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1- 6-alkyl, 3-6 membered heterocyclic C 1-6 alkyl;
[0014] Ring B is selected from C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 6-14 Aryl or 5-14 heteroaryl groups;
[0015] R5 is selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 alkyl.
[0016] m is selected from 0, 1, 2, 3, 4 or 5.
[0017] According to an embodiment of the present invention, R1 and R2 may be the same or different, and are independently selected from C. 1-3 Alkyl groups, such as methyl groups.
[0018] According to an embodiment of the present invention, R3 is selected from -NR c R d ;R c R d Whether the two are the same or different, they are selected independently from H and C. 1-3 alkyl;
[0019] According to an embodiment of the present invention, R3 is selected from -NH2.
[0020] According to an embodiment of the present invention, R4 is selected from hydrogen, C 1-3 alkyl.
[0021] According to an embodiment of the present invention, L is selected from sub-C 1-3 Alkyl groups; for example, methylene, ethylene.
[0022] According to an embodiment of the present invention, X is selected from CR x Y is selected from CR y Z is selected from N; R x R y Same or different, selected independently from C 1-3 Alkyl (e.g., methyl), C 1-3 Alkyl group.
[0023] According to an embodiment of the present invention, A is selected from...
[0024] According to embodiments of the present invention, ring B is selected from 5-10 membered heteroaryl groups, for example, selected from thiazolyl groups (such as...). ), imidazole, thiophene, pyrrole, furanyl, oxazolyl, isoxazolyl, pyridinyl or benzothiazolyl.
[0025] According to an embodiment of the present invention, R5 is selected from hydrogen, C 1-3 alkyl.
[0026] According to an embodiment of the present invention, A is selected from...
[0027] R1 and R2 may be the same or different, and are independently selected from C. 1-3 Alkyl groups, such as methyl groups.
[0028] According to an embodiment of the present invention, the compound represented by formula (I) is selected from the following structures:
[0029] According to an embodiment of the present invention, the compound represented by formula (I) is selected from the following structures:
[0030] According to an embodiment of the present invention, the drug is used to prevent, alleviate or treat fibrosis.
[0031] According to an embodiment of the present invention, the fibrosis is selected from pulmonary fibrosis, liver fibrosis, myocardial fibrosis, renal fibrosis, skin fibrosis, pancreatic fibrosis, intestinal fibrosis, and bone marrow fibrosis.
[0032] According to an embodiment of the present invention, the pulmonary fibrosis is selected from idiopathic pulmonary fibrosis, secondary pulmonary fibrosis, and pulmonary fibrosis caused by COVID-19; the liver fibrosis is selected from fibrosis or cirrhosis caused by chronic hepatitis (hepatitis B, hepatitis C), alcoholic liver disease, or non-alcoholic fatty liver disease; the myocardial fibrosis is selected from myocardial interstitial fibrosis after hypertension or myocarditis, and fibrosis in cardiac amyloidosis; the skin fibrosis is selected from scleroderma and radiation-induced skin fibrosis.
[0033] According to an embodiment of the present invention, the fibrosis is selected from TGF-β-induced fibrosis.
[0034] According to embodiments of the present invention, the compound represented by formula (I) significantly inhibits excessive deposition of extracellular matrix (ECM) by blocking the epithelial-mesenchymal transition (EMT) and / or fibroblast-myofibroblast transition (FMT) processes, exhibiting significant antifibrotic activity. Beneficial effects
[0035] The present invention has unexpectedly discovered that the compound represented by formula (I) or a pharmaceutically acceptable salt thereof has antifibrotic activity and can be used to prevent and / or treat fibrosis as well as to prepare antifibrotic drugs. Attached Figure Description
[0036] Figure 1 shows the results of the experiment on TGF-β-induced epithelial-mesenchymal transition (EMT) in A549 cells by compound P1.
[0037] Figure 2 shows the experimental results of TGF-β-induced fibroblast-myofibroblast transformation (FMT) in MRC-5 cells by compound P1.
[0038] Figure 3 shows the results of the experiment on TGF-β-induced epithelial-mesenchymal transition (EMT) in A549 cells by compound P2.
[0039] Figure 4 shows the results of the experiment on TGF-β-induced fibroblast-myofibroblast transformation (FMT) in MRC-5 cells by compound P2.
[0040] Figure 5 shows the experimental results of TGF-β-induced fibroblast-myofibroblast transformation (FMT) in LX-2 cells by compound P2.
[0041] Terminology Definitions and Explanations
[0042] Unless otherwise stated, the definitions of groups and terms recorded in this application specification and claims, including definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, and definitions of specific compounds in the examples, can be arbitrarily combined and combined with each other. Such combinations and combinations of group definitions and compound structures should be understood as being within the scope of this application specification and / or claims.
[0043] The term "alkyl" should be understood to refer to a straight-chain or branched saturated hydrocarbon group, preferably "C". 1-6 Alkyl group. "C" 1-6 "Alkyl" means a straight-chain or branched alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, or 1,2-dimethylbutyl, or their isomers.
[0044] The term "cycloalkyl" should be understood to refer to saturated monocyclic, bicyclic, or tricyclic alkanes, wherein the bicyclic or tricyclic ring can be a fused ring, a bridged ring, or a spiro ring, preferably "C". 3-6 cycloalkyl. The term "C" 3-6 "Cycloalkyl" should be understood to refer to saturated monocyclic, bicyclic, or bridged cycloalkanes having 3, 4, 5, or 6 carbon atoms. 3-6 Cycloalkyl groups can be monocyclic hydrocarbon groups, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0045] The term "heterocyclic group" refers to a saturated or unsaturated non-aromatic ring or ring system containing at least one, for example, 1, 2, 3, 4, 5 or more heteroatoms selected from O, S and N, wherein N and S may optionally be oxidized to various oxidation states to form nitrooxides, -S(O)- or -S(O)2- states, preferably "3- to 6-membered heterocyclic groups". The term "3- to 6-membered heterocyclic group" means a saturated or unsaturated non-aromatic ring or ring system containing at least one heteroatom selected from O, S and N. The heterocyclic group can be connected to the rest of the molecule via any one of the carbon atoms or a nitrogen atom (if present). The heterocyclic group can include fused or bridged rings and spirocyclic rings. In particular, the heterocyclic group may include, but is not limited to: 4-membered rings, such as azahexacyclic butyl or oxacyclic butyl; 5-membered rings, such as tetrahydrofuranyl, dioxacyclopentenyl, pyrrolyl, imidazoyl, pyrazolyl, or pyrrololinyl; or 6-membered rings, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazineyl, or trithiaalkyl.
[0046] The term "aryl" should be understood to refer to a monocyclic, bicyclic, or tricyclic hydrocarbon ring that is aromatic or partially aromatic, wherein the bicyclic or tricyclic ring can be a fused ring or a fused ring, preferably "C". 6-14 Aryl. The term "C" 6-14 "Aryl" should be understood to preferably represent an aromatic or partially aromatic monocyclic or bicyclic hydrocarbon ring having 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbon atoms, particularly a ring having 6 carbon atoms ("C6 aryl"), such as phenyl; or biphenyl, or a ring having 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl, or a ring having 10 carbon atoms ("C9 aryl"). 10 Aryl groups, such as tetrahydronaphthyl, dihydronaphthyl, or naphthyl, or rings with 13 carbon atoms (“C”). 13 Aryl groups, such as fluorene groups, or rings with 14 carbon atoms (“C”). 14 Aryl), such as anthracene. When the aryl group is substituted, it can be monosubstituted or polysubstituted. Furthermore, there are no restrictions on its substitution site; for example, it can be ortho, para, or meta substituted.
[0047] The term "heteroaryl" should be understood to include monocyclic, bicyclic, or tricyclic aromatic ring systems containing 1 to 5 heteroatoms independently selected from N, O, and S, wherein the bicyclic or tricyclic ring can be a fused ring or a fused ring, preferably a "5-14 membered heteroaryl". The term "5-10 membered heteroaryl" should be understood to include monocyclic, bicyclic, or tricyclic aromatic ring systems having 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 ring atoms, particularly 5, 6, 9, or 10 carbon atoms, and containing 1 to 5, preferably 1 to 3, heteroatoms independently selected from N, O, and S, and in each case may be benzofused. Specifically, the heteroaryl group is selected from thienyl, furanyl, pyrroleyl, oxazolyl, thiazolyl, imidazoleyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl, and their benzo[derivatives], such as benzofuranyl, benzothienyl, benzoxazolyl, benzoisoxazolyl, benzoimidazolyl, benzotriazolyl, indazole, indolyl, isindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and their benzo[derivatives], such as quinolinyl, quinazolinyl, isoquinolinyl, etc.; or acrylonitrileyl, inazinyl, purinyl, and their benzo[derivatives]; or terpineyl, phthalazinyl, quinazolinyl, quinoxolinyl, naphthidyl, pteridinyl, carbazolyl, acrylonitrileyl, phenazinyl, phenothiazinyl, phenothiazinyl, phenothiazinyl, etc. When the heteroaryl group is linked with other groups to form the compound of the present invention, the carbon atom on the heteroaryl ring may be linked with other groups, or the heteroatom on the heteroaryl ring may be linked with other groups. When the heteroaryl group is substituted, it may be monosubstituted or polysubstituted. Furthermore, there are no restrictions on the substitution site; for example, the hydrogen atom on the heteroaryl ring linked with a carbon atom may be substituted, or the hydrogen atom on the heteroaryl ring linked with a heteroatom may be substituted.
[0048] Unless otherwise stated, the term "compound" in the context of this invention should be understood to include the compound itself and its tautomers, stereoisomers, solvates or isotopic labels. Detailed Implementation
[0049] The technical solution of the present invention will be further described in detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanatory of the present invention, and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are covered within the scope of protection intended by the present invention.
[0050] Unless otherwise stated, the raw materials and reagents used in the following examples are commercially available products or can be prepared by known methods.
[0051] The preparation of compound P1 is described in patent document WO2023174397A1, and the preparation of compound P2 is described in patent document WO2023155892A1.
[0052] Example 1: Antifibrotic experiments of compounds P1 and P2 on various cell types.
[0053] Cell lines and cell culture
[0054] All cell lines were cultured at 37°C in a 5% CO2 incubator. A549 cells (ATCC) were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. LX-2 cells (ATCC) were cultured in DMEM medium containing 10% FBS and 1% penicillin-streptomycin. MRC-5 cells (ATCC) were cultured in MEM medium containing 10% FBS, 1% non-essential amino acids, 1 mM sodium pyruvate, and 1% penicillin-streptomycin. All cell lines were tested and confirmed to be free of mycoplasma contamination.
[0055] TGF-β-induced epithelial-mesenchymal transition (EMT) experiment in A549 cells
[0056] A549 cells were fed at a rate of 3 × 10 5 Cells were seeded at a density of 10 cells / well in six-well plates and cultured overnight. Cells were treated with three concentration gradients of compounds for 30 minutes, followed by stimulation with 10 ng / mL TGF-β for 72 hours. TGF-β stimulation served as a positive control. After induction, the culture medium was discarded, and the cells were washed once with PBS. Subsequently, RIPA lysis buffer (Beyotime, #P0013B) containing 1% protease inhibitor (Beyotime, #P1005) was added to the cell plate, and the cells were lysed on ice or at 4°C for 20 minutes, tapping the plate gently every 10 minutes to ensure complete cell lysis. The lysis buffer was collected using a cell scraper, centrifuged at 14,000 rpm for 15 minutes at 4°C, and the supernatant was collected and stored at -80°C for subsequent immunoblotting analysis.
[0057] TGF-β-induced fibroblast-myofibrillar transition (FMT) experiment in MRC-5 cells
[0058] MRC-5 cells were loaded at 4 × 10 5Cells were seeded at a density of 10 cells / well in six-well plates and cultured overnight. The cells were then replaced with serum-free medium and starved for 24 hours. Subsequently, cells were treated with three concentration gradients of compounds for 30 minutes each, followed by stimulation with 10 ng / mL TGF-β for 48 hours. After induction, the medium was discarded, and the cells were washed once with PBS. Then, RIPA lysis buffer (Beyotime, #P0013B) containing 1% protease inhibitor (Beyotime, #P1005) was added to the cell plate, and the cells were lysed on ice or at 4°C for 20 minutes, tapping the plate gently every 10 minutes to ensure complete lysis. The lysis buffer was collected using a cell scraper, centrifuged at 14,000 rpm for 15 minutes at 4°C, and the supernatant was collected and stored at -80°C for subsequent immunoblotting analysis.
[0059] TGF-β-induced fibroblast-myofibrillar transition (FMT) experiment in LX-2 cells
[0060] LX-2 cells were loaded at 4 × 10 5 Cells were seeded at a density of 100 cells / well in six-well plates and cultured overnight. The medium was then replaced with medium containing 0.5% fetal bovine serum (FBS) and starved for 24 hours. Cells were then treated with three concentration gradients of compounds for 30 minutes each, followed by stimulation with 10 ng / mL TGF-β for 48 hours. After induction, the medium was discarded, and the cells were washed once with PBS. Subsequently, RIPA lysis buffer (Beyotime, #P0013B) containing 1% protease inhibitor (Beyotime, #P1005) was added to the cell plate, and the cells were lysed on ice or at 4°C for 20 minutes, tapping the plate gently every 10 minutes to ensure complete lysis. The lysate was collected using a cell scraper, centrifuged at 14,000 rpm for 15 minutes at 4°C, and the supernatant was collected and stored at -80°C for subsequent immunoblotting analysis.
[0061] Immunoblotting
[0062] Protein concentrations in cell lysates were determined using the PIERCE BCA protein quantification kit (Invitrogen, #23225). After denaturation, samples were loaded onto 4–20% gradient Bis-Tris gels (GenScript, #M42012C) for protein separation by SDS-PAGE. After electrophoresis, proteins were transferred to nitrocellulose membranes (Invitrogen, #IB23001). The membranes were blocked for 1 hour at room temperature with TBST buffer containing 3% BSA (Beyotime, #ST023-200G), followed by overnight incubation with primary antibody at 4°C.
[0063] After primary antibody incubation, the membrane was washed three times with TBST buffer and then incubated with HRP-labeled secondary antibody at room temperature for 1 hour. Blot images were captured using an Azure Biosystems C300 imaging system and quantitative analysis was performed using AzureSpot Pro software.
[0064] Antibody
[0065] The antibodies used included: anti-E-cadherin (24E10) antibody (CST, #3195S), anti-N-cadherin (D4R1H) antibody (CST, #13116S), anti-fibronectin antibody (Abcam, #ab2413), anti-α-SMA (α-smooth muscle actin) antibody (D4K9N) antibody (CST, #19245S), anti-collagen I / III antibody (Abcam, #ab34710), anti-β-actin (D6A8) antibody (CST, #8457S), anti-GAPDH (14C10) antibody (CST, #2118S), and anti-rabbit IgG, HRP-labeled secondary antibody (CST, #7074P2).
[0066] The experimental results are shown in Figures 1 to 5. The results indicate that compounds P1 and P2 exhibited significant anti-fibrotic activity in various in vitro models. In TGF-β-induced A549 cells, P1 and P2 significantly inhibited the epithelial-mesenchymal transition (EMT) process in a dose-dependent manner. Furthermore, in TGF-β-stimulated MRC-5 cells, P1 and P2 dose-dependently inhibited the expression of fibrosis-related markers fibronectin and α-SMA, demonstrating their effective inhibition of fibroblast transformation into myofibroblasts. Notably, in TGF-β-induced LX-2 cells, compound P2 significantly reduced the synthesis levels of collagen I and III in a dose-dependent manner, proving its anti-fibrotic activity. These results suggest that compounds P1 and P2, by targeting the TGF-β signaling pathway and inhibiting key fibrotic processes such as EMT, myofibroblast activation, and ECM deposition, could be used to prepare anti-fibrotic drugs.
[0067] The embodiments of the technical solution of the present invention have been described above by way of example. It should be understood that the protection scope of the present invention is not limited to the above embodiments. Any modifications, equivalent substitutions, improvements, etc., made by those skilled in the art within the spirit and principles of the present invention should be included within the protection scope of the claims of this application.
Claims
1. The use of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of antifibrotic drugs; in, A is selected from R1 and R2 may be the same or different, and are independently selected from halogens and C. 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1- 6-alkyl, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1- 6-alkyl, 3-6 membered heterocyclic C 1-6 alkyl; R3 is selected from hydrogen, halogen, CN, OH, -OR a -NR c R d -C(=O)R a -C(=O)OR b -C(=O)NR c R d C 1-6 Alkyl, Halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 Alkyl; each R a R b R c R d Whether the two are the same or different, they are selected independently from H and C. 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 alkyl; R4 is selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 alkyl; L is selected from unsubstituted or optionally by one, two or more R. L Replaced sub-C 1-6 Alkyl; each R L They may be the same or different, and are independently selected from halogens, CN, OH, and C. 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 Alkyl; or two R L Composed of spirocyclic, aromatic, heterocyclic, or carbocyclic rings; X is selected from N or CR x ; Y is selected from N or CR y ; Z is selected from N or CR. z And at most two of X, Y, and Z are N; R x R y R z They are the same or different, and are independently selected from halogens and C. 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 alkyl; Ring B is selected from C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 6-14 Aryl or 5-14 heteroaryl groups; R5 is selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 3-6 cycloalkyl C 1-6 Alkyl, 3-6 membered heterocyclic C 1-6 alkyl. m is selected from 0, 1, 2, 3, 4 or 5.
2. The application according to claim 1, characterized in that, R1 and R2 may be the same or different, and are independently selected from C. 1-3 Alkyl groups, such as methyl groups.
3. The application according to claim 1 or 2, characterized in that, R3 is selected from -NR c R d ;R c R d Whether the two are the same or different, they are selected independently from H and C. 1-3 alkyl; Preferably, R3 is selected from -NH2; Preferably, R4 is selected from hydrogen, C 1-3 alkyl.
4. The application according to any one of claims 1-3, characterized in that, L is selected from Asia C 1-3 Alkyl groups; for example, methylene, ethylene.
5. The application according to any one of claims 1-4, characterized in that, X is selected from CR x Y is selected from CR y Z is selected from N; R x R y Same or different, selected independently from C 1-3 Alkyl (e.g., methyl), C 1- 3-alkoxy group.
6. The application according to any one of claims 1-5, characterized in that, A is selected from 7. The application according to any one of claims 1-6, characterized in that, Ring B is selected from 5-10 membered heteroaryl groups, for example, from thiazolyl groups (e.g., ...). ), imidazole, thiophene, pyrrole, furanyl, oxazolyl, isoxazolyl, pyridinyl or benzothiazolyl; Preferably, R5 is selected from hydrogen, C 1-3 alkyl.
8. The application according to any one of claims 1-7, characterized in that, The compound shown in formula (I) is selected from the following structures: Preferably, the compound represented by formula (I) is selected from the following structures:
9. The application according to any one of claims 1-8, characterized in that, The drug is used to prevent, alleviate, or treat fibrosis; Preferably, the fibrosis is selected from pulmonary fibrosis, liver fibrosis, myocardial fibrosis, renal fibrosis, skin fibrosis, pancreatic fibrosis, intestinal fibrosis, and bone marrow fibrosis; Preferably, the pulmonary fibrosis is selected from idiopathic pulmonary fibrosis, secondary pulmonary fibrosis, and pulmonary fibrosis caused by COVID-19; the liver fibrosis is selected from fibrosis or cirrhosis caused by chronic hepatitis (hepatitis B, hepatitis C), alcoholic liver disease, or non-alcoholic fatty liver disease; the myocardial fibrosis is selected from myocardial interstitial fibrosis after hypertension or myocarditis, and fibrosis in cardiac amyloidosis; the skin fibrosis is selected from scleroderma and radiation-induced skin fibrosis.
